Literature DB >> 17705290

Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration.

I Rite1, S Argüelles, J L Venero, S García-Rodriguez, A Ayala, J Cano, A Machado.   

Abstract

We have performed proteomic analysis in the cerebrospinal fluid in an animal model of Parkinson's disease induced by axotomy of the medial forebrain bundle. In this model, the degeneration of dopaminergic neurons was completed in 14 days, with a loss of about 50% dopaminergic neurons in the substantia nigra and a loss of more than 80% dopamine terminals in the striatum, with a similar diminution of dopamine levels in both structures. Proteins were separated by 2D electrophoresis and identified by matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF). We found significant increases of haptoglobin and transthyretin along with a decrease of Apo E concentrations in the cerebrospinal fluid of axotomized animals. Changes for haptoglobin and transthyretin were further confirmed in cerebrospinal fluid and plasma by Western blotting. These results suggest that monitoring plasma levels of these signals appears to be a promising biological marker of neuronal degeneration of the nigrostriatal dopaminergic system. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17705290     DOI: 10.1002/jnr.21452

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

1.  Varying nanoparticle pseudostationary phase plug length during capillary electrophoresis.

Authors:  Varuni Subramaniam; Lindsay Griffith; Amanda J Haes
Journal:  Analyst       Date:  2011-04-05       Impact factor: 4.616

2.  Proteome analysis of haptoglobin in cerebrospinal fluid of neuromyelitis optica.

Authors:  Shumei Bai; Shilian Liu; Xuxiao Guo; Zhaoyu Qin; Banqin Wang; Xiaohong Li; Yanjiang Qin
Journal:  Mol Biol Rep       Date:  2009-05-15       Impact factor: 2.316

Review 3.  Application of "omics" to prion biomarker discovery.

Authors:  Rhiannon L C H Huzarewich; Christine G Siemens; Stephanie A Booth
Journal:  J Biomed Biotechnol       Date:  2010-03-04

Review 4.  Glycoproteomics in neurodegenerative diseases.

Authors:  Hyejin Hwang; Jianpeng Zhang; Kathryn A Chung; James B Leverenz; Cyrus P Zabetian; Elaine R Peskind; Joseph Jankovic; Zhen Su; Aneeka M Hancock; Catherine Pan; Thomas J Montine; Sheng Pan; John Nutt; Roger Albin; Marla Gearing; Richard P Beyer; Min Shi; Jing Zhang
Journal:  Mass Spectrom Rev       Date:  2010 Jan-Feb       Impact factor: 10.946

5.  Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects.

Authors:  Chera L Maarouf; Thomas G Beach; Charles H Adler; Holly A Shill; Marwan N Sabbagh; Terence Wu; Douglas G Walker; Tyler A Kokjohn; Alex E Roher
Journal:  Neurol Res       Date:  2012-09       Impact factor: 2.448

Review 6.  Proteomics in animal models of Alzheimer's and Parkinson's diseases.

Authors:  Renã A Sowell; Joshua B Owen; D Allan Butterfield
Journal:  Ageing Res Rev       Date:  2008-07-18       Impact factor: 10.895

7.  Specific changes of serum proteins in Parkinson's disease patients.

Authors:  Wenwen Lu; Xinhua Wan; Bin Liu; Xianfang Rong; Lei Zhu; Pingping Li; Jiang Li; Ling Wang; Liying Cui; Xiaoliang Wang
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

8.  Salidroside ameliorates Parkinson's disease by inhibiting NLRP3-dependent pyroptosis.

Authors:  Xue Zhang; Yiming Zhang; Rui Li; Lingpeng Zhu; Buqing Fu; Tianhua Yan
Journal:  Aging (Albany NY)       Date:  2020-05-19       Impact factor: 5.682

9.  Meta-type analysis of dopaminergic effects on gene expression in the neuroendocrine brain of female goldfish.

Authors:  Jason T Popesku; Christopher J Martyniuk; Vance L Trudeau
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-02       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.